Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo Stock Exchange  >  Chugai Pharmaceutical Co., Ltd.    4519   JP3519400000

CHUGAI PHARMACEUTICAL CO., LTD.

(4519)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Tokyo Stock Exchange
11/18/2020 11/19/2020 11/20/2020 11/24/2020 11/25/2020 Date
4525 4575 4431 4562 4669 Last
1526000 2530800 1974500 2311100 2550700 Volume
+0.11% +1.10% -3.15% +2.96% +2.35% Change
Financials
Sales 2020 762 B 7 294 M 7 294 M
Net income 2020 216 B 2 065 M 2 065 M
Net cash position 2020 403 B 3 852 M 3 852 M
P/E ratio 2020 35,7x
Yield 2020 1,13%
Sales 2021 833 B 7 973 M 7 973 M
Net income 2021 250 B 2 393 M 2 393 M
Net cash position 2021 496 B 4 748 M 4 748 M
P/E ratio 2021 31,0x
Yield 2021 1,40%
Capitalization 7 675 B 73 525 M 73 442 M
EV / Sales 2020 9,54x
EV / Sales 2021 8,62x
Nbr of Employees 7 394
Free-Float 37,7%
More Financials
Company
Chugai Pharmaceutical Co. Ltd specializes in the research, development, manufacturing and marketing of drugs especially for cancers (40.8% of net sales), bones and joints diseases treatment (18.4%), and kidney diseases (5.9%). Net sales are distributed geographically as follows: Japan (74,3%), Switzerland (22,8%) and other (2,9%). 
More about the company
Notations Surperformance© of Chugai Pharmaceutical Co., Ltd.
Trading Rating : Investor Rating :
More Ratings
All news about CHUGAI PHARMACEUTICAL CO., LTD.
09:56aChugai and DeNA Jointly Launch 'Ring Again,' a Rheumatoid Arthritis Disease A..
AQ
11/20CHUGAI PHARMACEUTICAL : Receives the Best IR Award
AQ
11/18CHUGAI PHARMACEUTICAL : Selected for the First Time in the 'DJSI World,' a Globa..
AQ
11/06CHUGAI PHARMACEUTICAL : Contributes Fourteen Thousand Tons of CO2 Emission Reduc..
AQ
10/30CHUGAI PHARMACEUTICAL : Results from the Investigator-Initiated Phase I Study of..
AQ
10/29CHUGAI PHARMACEUTICAL : Contribution of Para-transit Vehicles to Welfare Service..
AQ
10/23CHUGAI PHARMACEUTICAL : Announces 2020 3rd Quarter Results
AQ
10/22Japan stocks end lower as firmer yen, U.S. political uncertainty weigh
RE
10/21Japanese shares fall on rising yen, U.S. political uncertainty
RE
10/21PTC Therapeutics Says Evrysdi Approved in Brazil, Japan NDA Filed
DJ
10/20Chugai and Welby Launch a Treatment Support Personal Health Record Service fo..
AQ
10/19CHUGAI PHARMACEUTICAL CO., LTD. : quaterly earnings release
10/16CHUGAI PHARMACEUTICAL : Files a New Drug Application for Risdiplam as the First ..
AQ
10/07CHUGAI PHARMACEUTICAL : enters into a License Agreement for 's Antibody Engineer..
AQ
10/05CHUGAI PHARMACEUTICAL : Files for Expanded Use of FoundationOne CDx Cancer Genom..
AQ
More news
News in other languages on CHUGAI PHARMACEUTICAL CO., LTD.
10/19CHUGAI PHARMACEUTICAL CO., LTD. : Veröffentlichung des Quartalsergebnisses
10/19CHUGAI PHARMACEUTICAL CO., LTD. : publication des résultats trimestriels
10/16TOUR DU MONDE DES INDICES : De l’équilibrisme à l’or bleu
10/15ROCHE : Chugai dépose une demande d'homologation pour Risdiplam
09/25ROCHE : extension d'homologation pour Tecentriq et Avastin au Japon
More news
Analyst Recommendations on CHUGAI PHARMACEUTICAL CO., LTD.
More recommendations
Stock Trading Strategies
CHUGAI PHARMACEUTICAL CO., LTD. - 05/18
The trend should regain control
BUY
More Stock Trading Analysis
Chart CHUGAI PHARMACEUTICAL CO., LTD.
Duration : Period :
Chugai Pharmaceutical Co., Ltd. Technical Analysis Chart | 4519 | JP3519400000 | MarketScreener
Technical analysis trends CHUGAI PHARMACEUTICAL CO., LTD.
Short TermMid-TermLong Term
TrendsBullishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Average target price 4 864,75 JPY
Last Close Price 4 669,00 JPY
Spread / Highest target 34,9%
Spread / Average Target 4,19%
Spread / Lowest Target -20,8%
EPS Revisions
Managers
NameTitle
Tatsuro Kosaka Chairman & Chief Executive Officer
Osamu Okuda President, COO & Representative Director
Itagaki Toshiaki CFO, Manager-Information Technology & Accounting
Hisafumi Okabe Senior Executive Officer & Head-Research
Junichi Nezu Executive Officer, GM-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
CHUGAI PHARMACEUTICAL CO., LTD.38.96%71 666
JOHNSON & JOHNSON-1.37%378 744
ROCHE HOLDING AG-4.28%281 946
PFIZER INC.-6.59%203 437
MERCK & CO., INC.-11.89%202 757
NOVARTIS AG-12.66%200 273